clinical trial · NCT07282509
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·phase2·not yet recruiting·n = 116
Advanced Hepatocellular Carcinoma (HCC)HA131Enlonstobart InjectionPembrolizumab InjectionLenvatinib Mesilate Capsules
brief summary
This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC). Its primary objective is to evaluate the safety, tolerability, pharmacokinetic profiles, and efficacy of transcatheter arterial infusion of HA131 combined with systemic therapy in the second-line treatment of participants with advanced HCC.
started
Dec 23, 2025
primary completion
Jun 26, 2028
completion
Feb 3, 2029
last updated
Dec 15, 2025
official title
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of Transcatheter Arterial Infusion of Paclitaxel Cationic Liposome Combined With Systemic Therapy in Participants With Advanced Hepatocellular Carcinoma for Second-line Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol